Pfizer Pipeline Update Includes Resubmission Plans For Osteoporosis Drug Lasofoxifene
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.
The pharma giant has 85 new molecular entities in development, with 99 total programs in Phase I through Phase III.